This Amendment No. 2 (this “Final Amendment”) relates to the Issuer Tender Offer Statement
on Schedule TO originally filed on October 16, 2026, as amended and supplemented by Amendment No. 1 to the Issuer Tender Offer Statement on Schedule TO filed on November 18, 2026 (together, the “Schedule TO”), by BlackRock
Health Sciences Term Trust, a Maryland statutory trust (the “Fund”), pursuant to Rule 13e-4 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in connection
with an offer by the Fund (the “Offer”) to repurchase up to 5% of its issued and outstanding common shares of beneficial interest, par value $0.001 per share (the “Shares”), in exchange for cash at a price equal to 98% of the
net asset value (“NAV”) per Share determined as of the close of the regular trading session of the New York Stock Exchange, the principal market on which the Shares are traded, on the next day the NAV is calculated after the Offer
expires, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated October 16, 2026 (the “Offer to Purchase”), and in the related Letter of Transmittal, copies of which were previously filed as Exhibits
(a)(1)(i) and (a)(1)(ii), respectively, to the Schedule TO.
This is the Final Amendment to the Schedule TO and is being filed to report the results of
the Offer and to update Item 12 of the Schedule TO to include a press release announcing the final results of the Offer. A copy of the press release is attached hereto as Exhibit (a)(5)(iii). Capitalized terms not otherwise defined herein shall have
the meanings ascribed to them in the Offer to Purchase or the Schedule TO.
The following information is furnished to satisfy the requirements of Rule 13e-4(c)(4) under the Exchange Act:
| |
1. |
The Offer expired at 5:00 p.m. Eastern time, on November 18, 2026. |
| |
2. |
The Offer was oversubscribed. Therefore, in accordance with the terms of the Offer, the Fund will purchase
Shares from all tendering shareholders on a pro rata basis, after disregarding fractions, based on the number of Shares properly tendered. 13,178,845 Shares of the Fund were validly tendered and not withdrawn prior to the expiration of the
Offer, and 3,125,070 of those Shares were accepted for repurchase by the Fund in accordance with the terms of the Offer. |
| |
3. |
The Shares will be repurchased at a price of $17.8458, which is equal to 98% of the Fund’s NAV per Share
as of November 19, 2026. |
Except as specifically provided herein, this Final Amendment does not modify any of the information
previously reported in the Schedule TO, as amended, or the Letter of Transmittal.
Item 1 through Item 9 and Item 11
The information set forth in the Offer to Purchase and the related Letter of Transmittal is incorporated by reference into this Final Amendment in answer to
Item 1 through Item 9 and Item 11 of the Schedule TO.
Item 10. Financial Statements
(a) The audited annual financial statements of the Fund dated December 31, 2025 and the schedule of investments of the Fund dated
December 31, 2025, both filed with the SEC on EDGAR on Form N-CSR on March 5, 2026, are incorporated by
reference. The unaudited semi-annual financial statements of the Fund dated June 30, 2026 and the schedule of investments of the Fund dated June
30, 2026, both filed with the SEC on EDGAR on Form N-CSRS on September 3, 2026, are incorporated by
reference.
(b) Not applicable.
Item 12(a). Exhibits
Item 12(a) of
the Schedule TO is hereby amended and supplemented to add the following exhibit:
(a)(5)(iii) Press release issued on November 19,
2026 is filed herewith.
Item 12(c). Filing Fees
Filing Fee Exhibit is filed herewith.
Item 13. Information Required By Schedule 13E-3
Not applicable.